Elixir Medical Corp

FOR POLISH PHYSICIANS: Join us for an upcoming webinar hosted in partnership with Asocjacja Interwencji Sercowo-Naczyniowych (@AISNPL) and Elixir Medical, focused on real-world experiences with LithiX IVL technology. LithiX Hertz Contact Stress IVL - A New Approach to Calcium…

Leave nothing behind or leave the right thing in place? Fascinating comparison of drug-coated balloons (DCB) and the bioadaptor in treatment of de novo coronary lesions presented by Dr. @DavidErlinge at @TCTMD 2025. 2-year clinical outcomes of patients undergoing PCI captured…

It’s the final day of @TCTMD 2025! We have enjoyed connecting with colleagues from around the world and are looking forward to hearing these podium presentations today. 🗓️ Tuesday, October 28 8:40 AM – Computational Fluid Dynamic and Morphometric Analysis of the Novel DynamX®…

Massive update on the shifting PCI paradigm released at @TCTMD 2025. 2-year clinical outcomes of the INFINITY-SWEDEHEART RCT presented by Dr. @DavidErlinge, on behalf of Dr. Stefan James and the INFINITY-SWEDEHEART Investigators. Large (2,400 patients) RCT shows continuing…

Elixir Medical is live at Day 3 of TCT 2025! Don’t miss these key presentations on Elixir Medical technologies: 🗓️ Monday, October 27 11:00 AM – Challenging Case of Heavily Calcified CTO Treated With New Lithotripsy Device – LithiX Hertz Contact Intravascular Lithotripsy…

Congratulations Dr. Sahbi Fradi for your insightful presentation of “Calcium Modification in Complex PCI Using the LithiX HC-IVL System” at @TCTMD 2025. This is a great example of resolving a large calcific nodule “with procedural efficiency” and “eliminating the need for…

Exciting data revealed today at @TCTMD 2025! Dr. @JohanBennett2 presented “Three Year Outcomes in Patients with LAD Lesions Treated with DynamX Bioadaptor Compared to a Contemporary DES from the BIOADAPTOR RCT Trial.” Results show durable and significant benefits of bioadaptor…

Elixir Medical is live at @TCTMD 2025 in San Francisco! Our team is excited to be here, where new clinical data and real-world insights in interventional cardiology will be presented. Check out these innovation-driven podium presentations today and tomorrow. 🗓️ Saturday,…

We’re looking forward to the start of @TCTMD 2025 tomorrow in San Francisco! Elixir Medical is honored to share new data and real-world insights throughout the meeting at a variety of podium sessions, including our Symposium on Sunday, October 26 at 2:00 p.m. Join us as the…

Don’t miss Elixir Medical’s symposium at @TCTMD 2025! Rethinking PCI Success: Is It Time to Move Beyond Stents for Lasting Patient Outcomes? 📅 Sunday, October 26 | 2:00–3:15 PM 📍 Presentation Theater 4 | Hall E Moderated by Dr. Shigeru Saito and Dr. Robert Yeh, this…

We look forward to joining the global cardiovascular community at @TCTMD 2025, October 25–28 at the Moscone Center in San Francisco. Elixir Medical will present new clinical data, complex real-world cases, and expert insights across a range of podium sessions, including: –…

Elixir Medical is proud to participate in @CVPrevInterv 2025 in Warsaw, contributing to the evolving discussion on calcium modifications, imaging and optimized PCI strategies. 📍 October 10 | ROOM C | 12:00–16:30 Modern PCI Strategies in Clinical Practice – From Imaging to…

Elixir Medical is pleased to join the conversation at @OptimaCTO PCI 2025 in London on October 10 with faculty presenting in both the live case and interactive learning sessions. 📍 11:00–12:00 | Live Cases 5 & 6 Broadcast from St George’s, University NHS Trust (London)…

Elixir Medical is pleased to take part in @sicigise 2025 in Milan. We are proud to have our technologies being showcased during few sessions exploring advanced strategies in PCI and calcium modifications. Join us to learn how our Bioadaptor and LithiX HC-IVL could make a…

Are you @GRCIcardio? Join today Friday, Sept 26 at 13:40 Benoit Latucca, Charlotte Trouillet, @bouissetfred and Pierre Robert. They will discuss real-world cases featuring LithiX HC-IVL in eccentric and nodular calcified coronary lesions. Learn how our novel lithotripsy tool is…

We’re headed to @GRCIcardio 2025 in Paris! Catch our session on LithiXHC-IVL—a novel tool for calcium modification—on Sept 26 from 13:40–14:00. Real-world cases of nodular & eccentric calcified lesions will be presented by a panel of leading physicians: Benoit Latucca,…

DynamX bioadaptor demonstrates a low TLF rate, independent of lesion complexity. DynamX’s clinically significant results compared to DES can be attributed to bioadaptor’s mechanism of action of restoring pulsatility, compliance, and adaptive remodeling. View Dr. Holger Nef’s…

The DynamX bioadaptor offers physicians an alternative to DES that can restore coronary arteries to a more natural state after PCI with long-term benefits to the patient. But what does that look like in real life? “JACC: Case Reports” published an article where the authors…

Thank you to everyone who joined our webinar with CUHK Medical Centre on Advancing PCI with Bioadaptive Angioplasty. We’re grateful to our speakers for sharing meaningful data and case experiences. If you missed the session, we’ll be sharing access to recordings and highlights…